following a full submission:
ertugliflozin (Steglatro®) is accepted for restricted use within NHSScotland.
Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
- As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.
- In addition to other medicinal products for the treatment of diabetes.
SMC restriction: ertugliflozin is accepted for use as monotherapy and as add-on therapy. When used as monotherapy it is restricted to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and in whom a sulphonylurea or pioglitazone is not appropriate.
ertugliflozin was superior to placebo in lowering HbA1c in adults with type 2 diabetes mellitus in phase III studies in monotherapy, dual therapy and triple therapy settings.
Medicine details
- Medicine name:
- ertugliflozin (Steglatro)
- SMC ID:
- SMC2102
- Indication:
In adults aged 18 years and older with T2DM as an adjunct to diet and exercise to improve glycaemic control: • As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. • In addition to other medicinal products for the treatment of diabetes.
- Pharmaceutical company
- MSD
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 14 January 2019